


Vadim Le Joncour
Ohjaaja tohtorihjelmassa, dosenttuuri, tutkijatohtori
Doctoral Programme in Biomedicine
Neurotieteen tutkimuskeskus
Tiedekunnan yhteiset (Lääketieteellinen tiedekunta)
Osoitetyyppi: Postiosoite.
Suomi
Osoitetyyppi: Postiosoite.
PL 63 (Haartmaninkatu 8)
00014
Suomi
Sähköposti: vadim.lejoncour@helsinki.fi
Matkapuhelin: +358504486408
Puhelin: +358294125579



Ansio luettelo

Personal details

Last, first name	Le Joncour, Vadim	Nationality:	French
Place of birth:	Rouen, France	Year of birth:	1985
ORCID:	0000-0001-8153-8563	ResearcherID:	X-6274-2019

Current affiliation: University of Helsinki, Helsinki Institute for Life Sciences (HiLIFE), Neuroscience Center and iCAN Flagship Digital Precision Cancer Medicine, Haartmaninkatu 8, 00290 Helsinki, Finland.

Degrees

2023 **Title of Docent**, Cancer Biology. Faculty of Medicine, University of Helsinki
2015 **Doctor of Philosophy**, *Implication of the urotensinergic system in neo-angiogenesis and invasion mechanisms of high-grade glioma*, Faculty of Science, University of Rouen, France
2010 Master of Science, Cellular and Molecular Neuroscience and Neuroendocrinology, Faculty of Science, University of Rouen, France
2008 Bachelor of Science, Life sciences – Animal Physiology, Neuroscience and Neuropsychology, Faculty of Science, University of Rouen, France

Current positions

2023 – 2028 **University Researcher** *Neuroplasticity and Neurotrophic Factors lab* (Research Director: Eero Castrén, M.D., Ph.D.).

Junior Team Leader *Neo[plastic] Brain Team*. HiLIFE, Neuroscience Center, University of Helsinki, Finland

2024 – 2026 **Co-Principal Investigator** *iCAN-Plasticity: Neuroplasticity in clinical cancer*. University of Helsinki, Finland.

Research output

2011 – 2024 **Total number of peer reviewed publications: 27**; conference proceedings: 11.

H-index: 16 (Web of Science) 16 (Google Scholar)

Number of times cited: 600 (Web of Science) 783 (Google Scholar)

2021 – 2024 Invention disclosure: UH ID No. 1121/2021 '*Navigator*: Peptide-based delivery of diagnostic tools and therapeutics to brain metastases'.

Research to Business (TUTL) 1051/31/2022. *Navigator* - novel tool for early brain metastases diagnostics. Helsingin Yliopisto.

Patent Pending on *Navigator*.

Previous work experience

2022 – 2023 iCAN Flagship Digital Precision Cancer Medicine, *iCAN-Brain: Deciphering the Dialogue between Astrocytes and Brain Tumors*. Faculty of Medicine, University of Helsinki, Finland

2019 – 2022 **Academy of Finland Post-doctoral Fellow** *The Mechanistic and Transcriptomic Signature of Brain Tumor Invasion*. CAN-PRO, University of Helsinki, Finland.

2015 – 2019 Post-doctoral researcher. *Research of novel molecular and cellular targets for glioblastoma and brain metastasis treatment*. Tumor Progression and Metastasis Lab (Lab. Head: Pirjo Laakkonen, Ph.D.), Research Programs Unit, Translational Cancer Biology, Faculty of Medicine, University of Helsinki, Finland

2013 – 2014 University lecturer & research assistant. Inserm U982/ANiVas lab. (Dir.: Hélène Castel, Ph.D.) University of Rouen, France

09.2010 – 06.14 Doctoral researcher, Inserm U982/ANiVas lab. (Dir.: Hélène Castel, Ph.D.) University of Rouen, France

Research funding and grants

Obtained as principal investigator

2025– 2028 Research Grant from the Finnish Cancer Society (EUR 181332) for *Modulators of neuronal plasticity for brain tumor cells reprogramming*

2024 Research Grant from the Finnish Cancer Society (EUR 50000) for *Modulators of neuronal plasticity for brain tumor cells reprogramming*

2023 Research Grant from the Magnus Ehrnrooth Foundation (EUR 5000) for *Neurodevelopmental features of the Neoplastic brain*

2022 Research Grant from the Magnus Ehrnrooth Foundation (EUR 5000) for *Mapping invasive glioblastoma cells reprogramming into neuron-like cells*

Maupertuis Programme (EUR 1200) collaborative grant for the scientific cooperation between the Seano (Institut Curie, FR) and Le Joncour (Helsinki University, FIN) Labs

2021 Research Grant from the Magnus Ehrnrooth Foundation (EUR 8000) for *Revealing the invasive brain tumor cell identity*

Personal grant from K. Albin Johansson stiftelse (EUR 5000) for *Mapping brain tumor cells' reprogramming and invasion*

2020 Research Grant from the Magnus Ehrnrooth foundation (EUR 5000) for *Cationic amphiphilic molecules to treat invasive brain tumors*

2019 – 2022 Academy of Finland Postdoc fellowship *Investigating the transcriptomic and mechanistic signature of invasive gliomas*, University of Helsinki, Finland (EUR 290,000)

2019 Personal grant from K. Albin Johansson stiftelse (EUR 5000) for *Investigating the transcriptomic and mechanistic signature of invasive gliomas*

Awards and honors and academic merits

2022 **Best presentation** price at the Scandinavian Society of Neuro-Oncology (200+ participants). Helsinki, Finland <https://bit.ly/3LYTm8i>

Invited talks Université de Nantes, France (06.2021), Cardiff University, UK (03.2022), 10x Genomics, Helsinki (05.2022), Institut Curie, Paris (06.2022) <https://bit.ly/3cy8j5r>, Normandie Universités, France (06.2022), HiLIFE, Neuroscience Center (04.2023), Lundbeck Foundation (02.2024).

2020 & 2022 Organizer of the 1st & 3rd FiBTRA Virtual seminar (27.10.2022) <https://bit.ly/3CFhtY2>

2021 – 2022 Senior evaluator for the EuroTechPostdoc2 2021 & 2022 calls, Marie Skłodowska-Curie fellowship programme

2019 Award at the Finnish Brain Tumor Research Association (FiBTRA) (80+ participants). Helsinki, Finland.

2015 & 2019 Co-organizer of the FiBTRA annual meetings (Helsinki, Finland, 80+ participants)

2016 – Review of 30+ research and 3 review articles

2015 – Board, Finnish Brain Tumor Research Association http://fibtra.org/fibtra_board.html

Työsuhteet

Ohjaaja tohtorihjelmassa

Doctoral Programme in Biomedicine

Helsingin yliopisto

Suomi

1 tammik. 2015 → present

tutkijatohtori

Neurotieteen tutkimuskeskus

Helsingin yliopisto

Suomi

1 toukok. 2023 → present

dosenttuuri

Tiedekunnan yhteiset (Lääketieteellinen tiedekunta)

Helsingin yliopisto

Suomi

24 maalisk. 2023 → present

Tutkimustuotos

Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan

Pourjamal, N., Le Joncour, V., Vereb, G., Honkamäki, C., Isola, J., Leyton, J. V., Laakkonen, P., Joensuu, H. & Barok, M., maalisk. 2025, julkaisussa: *Translational oncology*. 53, 9 Sivumäärä, 102284.

Supersoft Sponge-like Cryogel As an Implant to Treat Glioblastoma

Wang, Y., Le Joncour, V., Laakkonen, P. & Newland, B., 15 lokak. 2024, julkaisussa: *Neuro-Oncology*. 26, Supplement 7, s. vii16 1 Sivumäärä

Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model

Pourjamal, N., Yazdi, N., Halme, A., Le Joncour, V., Laakkonen, P., Saharinen, P., Joensuu, H. & Barok, M., 2024, julkaisussa: *Clinical and Experimental Metastasis*. 41, s. 91–10 12 Sivumäärä

Heparin-Derived Theranostic Nanoprobes Overcome the Blood-Brain Barrier and Target Glioma in Murine Model

Samanta, S., Le Joncour, V., Wegrzyniak, O., Rangasami, V. K., Ali-Loytty, H., Hong, T., Selvaraju, R. K., Aberg, O., Hilborn, J., Laakkonen, P., Varghese, O. P., Eriksson, O., Cabral, H. & Oommen, O. P., kesäk. 2022, julkaisussa: *Advanced Therapeutics*. 5, 6, 17 Sivumäärä, 2200001.

Bivalent EGFR-Targeting DARPIn-MMAE Conjugates

Karsten, L., Janson, N., Le Joncour, V., Alam, S., Müller, B., Tanjore Ramanathan, J., Laakkonen, P., Sewald, N. & Mueller, K. M., maalisk. 2022, julkaisussa: *International Journal of Molecular Sciences*. 23, 5, 26 Sivumäärä, 2468.

Peptidotriazolamers Inhibit A beta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model

Tonali, N., Hericks, L., Schroeder, D. C., Kracker, O., Krzemieniecki, R., Kaffy, J., Le Joncour, V., Laakkonen, P., Marion, A., Onger, S., Doder, V. I. & Sewald, N., kesäk. 2021, julkaisussa: *ChemPlusChem*. 86, 6, s. 840-851 12 Sivumäärä

Redox responsive Pluronic micelle mediated delivery of functional siRNA: a modular nano-assembly for targeted delivery

Kadekar, S., Nawale, G., Rangasami, V., Le Joncour, V., Laakkonen, P., Hilborn, J., Varghese, O. & Oommen, O., kesäk. 2021, julkaisussa: *Biomaterials Science*. 9, 11, s. 3939-3944 6 Sivumäärä

Circumventing Drug Treatment? Intrinsic Lethal Effects of Polyethyleneimine (PEI)-Functionalized Nanoparticles on Glioblastoma Cells Cultured in Stem Cell Conditions

Prabhakar, N., Merisaari, J., Le Joncour, V., Peurla, M., Sen Karaman, D., Casals, E., Laakkonen, P., Westermarck, J. & Rosenholm, J. M., 27 toukok. 2021, julkaisussa: *Cancers*. 13, 11, 19 Sivumäärä, 2631.

CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity

Filppu, P., Ramanathan, J. T., Granberg, K. J., Gucciardo, E., Haapasalo, H., Lehti, K., Nykter, M., Le Joncour, V. & Laakkonen, P., 10 toukok. 2021, julkaisussa: *JCI INSIGHT*. 6, 9, 21 Sivumäärä, 141486.

Prostate-specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain

Ramanathan, J. T., Lehtipuro, S., Sihto, H., Tovari, J., Reiniger, L., Teglas, V., Moldvay, J., Nykter, M., Haapasalo, H., Le Joncour, V. & Laakkonen, P., kesäk. 2020, julkaisussa: *Journal of Cellular and Molecular Medicine*. 24, 12, s. 6916-6927 12 Sivumäärä

Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) is a biomarker of poor prognosis in primary melanomas and its depletion inhibits melanoma cell invasion and disrupts tumor blood vessel walls

Eriksson, J., Le Joncour, V., Jahkola, T., Juteau, S., Laakkonen, P., Saksela, O. & Hölttä, E., huhtik. 2020, julkaisussa: *Molecular oncology*. 14, 4, s. 742-762 21 Sivumäärä

ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer

Barok, M., Le Joncour, V., Martins, A., Isola, J., Salmikangas, M., Laakkonen, P. & Joensuu, H., 2020, julkaisussa: *Cancer Letters*. 473, s. 156-163 8 Sivumäärä

Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma

Merisaari, J., Denisova, O., Doroszko, M., Le Joncour, V., Johansson, P., Leenders, W. P. J., Kastrinsky, D. B., Zaware, N., Narla, G., Laakkonen, P., Nelander, S., Ohlmeyer, M. & Westermarck, J., 2020, julkaisussa: *Brain communications*. 2, 1, 12 Sivumäärä, 02.

A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine

Le Joncour, V., Martins, A., Puhka, M., Isola, J., Salmikangas, M., Laakkonen, P., Joensuu, H. & Barok, M., lokak. 2019, julkaisussa: *Molecular Cancer Therapeutics*. 18, 10, s. 1721-1730 10 Sivumäärä

Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization

Le Joncour, V., Filppu, P., Hyvönen, M., Holopainen, M., Turunen, S. P., Sihto, H., Burghardt, I., Joensuu, H., Tynninen, O., Jääskeläinen, J., Weller, M., Lehti, K., Käkälä, R. & Laakkonen, P., kesäk. 2019, julkaisussa: *EMBO molecular medicine*. 11, 6, 21 Sivumäärä, 9034.

Octreotide Conjugates for Tumor Targeting and Imaging

Figueras, E., Martins, A., Borbely, A., Le Joncour, V., Cordella, P., Perego, R., Modena, D., Pagani, P., Esposito, S., Auciello, G., Frese, M., Gallinari, P., Laakkonen, P., Steinkuhler, C. & Sewald, N., toukok. 2019, julkaisussa: *Pharmaceutics*. 11, 5, 14 Sivumäärä, 220.

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish

Le Joncour, V., Karaman, S. & Laakkonen, P. M., 16 huhtik. 2019, julkaisussa: *Journal of Visualized Experiments*. 146, 12 Sivumäärä, 59384.

Seek & Destroy, use of targeting peptides for cancer detection and drug delivery

Le Joncour, V. & Laakkonen, P., 1 kesäk. 2018, julkaisussa: *Bioorganic & Medicinal Chemistry*. 26, 10, s. 2797-2806 10 Sivumäärä

Targeting peptides, a Swiss-army knife against cancer

Le Joncour, V. J. M. & Laakkonen, P., 2018, *Amino Acids, Peptides and Proteins*. Ryadnov, M. & Hudecz, F. (toim.). Royal Society of Chemistry, Vuosikerta 42. s. 281-320 40 Sivumäärä

Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression

Eriksson, J., Le Joncour, V., Nummela, P., Jahkola, T., Virolainen, S., Laakkonen, P., Saksela, O. & Hölttä, E., 22 maalisk. 2016, julkaisussa: *Oncotarget*. 7, 12, s. 15065-15092 28 Sivumäärä

Aktiviteetit

Finnish Brain Tumor Research Association Annual Meeting: FiBTRA 2019

Laakkonen, P. (Järjestäjätoimikunnan jäsen), Le Joncour, V. (Järjestäjätoimikunnan jäsen) & Filppu, P. (Järjestäjätoimikunnan jäsen)
31 lokak. 2019 → 1 marrask. 2019

Oral presentation to FiBTRA 2017

Le Joncour, V. (Puhuja)
27 lokak. 2017

Finnish Brain Tumor Research Association Annual Meeting

Le Joncour, V. (Järjestäjätoimikunnan jäsen), Laakkonen, P. M. (Järjestäjätoimikunnan jäsen), Filppu, P. I. (Osallistuja), Tanjore Ramanathan, J. (Osallistuja), Ayo, A. O. (Osallistuja), Ylä-Herttua, S. (Puhuja: pääpuhujana (keynote)) & Westermarck, J. (Järjestäjätoimikunnan jäsen)
1 marrask. 2016 → 2 marrask. 2016

Presentation to the Magic Bullet Network Meeting

Le Joncour, V. (Puhuja)
19 heinäk. 2016

Palkinnot

FiBTRA 2019 selected talk

Le Joncour, V. (Vastaanottaja), 1 marrask. 2019

K. Albin Johansson foundation

Le Joncour, V. (Vastaanottaja), 11 jouluk. 2019

Lehdistö/media

Cover of the EMBO Molecular Medicine journal

Le Joncour, V.

07/06/2019

1 kohde/ Medianäkyvyys

Exploiting a Chink in the Armor of Brain Tumor Cells

Laakkonen, P. & Le Joncour, V.

13/05/2019

1 kohde/ Medianäkyvyys

Researchers discover the Achilles' heel of an aggressive brain cancer

Sihto, H., Joensuu, H., Laakkonen, P. & Le Joncour, V.

10/05/2019 → 13/05/2019

8 kohdetta/ Medianäkyvyys

-UNIVERSITY OF HELSINKI: Researchers discover the Achilles' heel of an aggressive brain cancer - could antihistamine be a potential aid in defeating cancerous cells?

Sihto, H., Joensuu, H., Laakkonen, P. & Le Joncour, V.

13/05/2019

1 kohde/ Medianäkyvyys